TY - JOUR
T1 - Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study
AU - Garcia-Soto, Arlene E.
AU - Java, James J.
AU - Nieves Neira, Wilberto
AU - Pearson, J. Matthew
AU - Cohn, David E.
AU - Lele, Shashikant B.
AU - Tewari, Krishnansu S.
AU - Walker, Joan L.
AU - Alvarez Secord, Angeles
AU - Armstrong, Deborah K.
AU - Copeland, Larry J.
N1 - Funding Information:
The following National Cancer Institute grants also supported this study: NRG Oncology Operations grant number U10 CA 180868 as well as NRG SDMC grant U10 CA180822 , Gynecologic Oncology Group (GOG) ( U10 CA180822 ), Administrative Office and GOG Tissue Bank ( CA 114793 ).
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016
Y1 - 2016
N2 - Objectives To determine the relationship of the time from surgery to intraperitoneal (IP) chemotherapy (TSIC) initiation with survival of patients with stage III epithelial ovarian cancer (EOC) patients using ancillary data from cooperative group clinical trials. Methods Data from 420 patients with stage III EOC treated with IP chemotherapy under GOG-0114 and 172 were reviewed. The Cox proportional hazards model was used to evaluate independent prognostic factors and estimate their covariate-adjusted effects on PFS and OS. Results The median TSIC was 62.5 days (interquartile range 28–83). The median TSIC was longer for patients in GOG-0114 vs those in GOG-172 (83 vs 26 days, p < 0.001). TSIC was significantly associated (p = 0.049) with PFS: each 10% increase in TSIC (days) decreases the risk of progression by 3%. TSIC was not significantly associated with OS in this model. In a linear regression model, gross residual disease was significantly associated with shorter TSIC (R2 − 0.141, 95%CI − 0.217, − 0.064, p < 0.001). When only data from GOG-172 were considered, no statistical significant association was found between TSIC and PFS or OS. Conclusions In this ancillary data study, TSIC was not associated with improved OS in patients with stage III epithelial ovarian cancer. TSIC was significantly associated with PFS for the entire cohort, suggesting increase in PFS with longer TSIC. However, this was not found when only data from GOG 172 or GOG 114 were analyzed separately. Hence, the relationship between IP chemotherapy initiation and time from surgery needs to be studied further.
AB - Objectives To determine the relationship of the time from surgery to intraperitoneal (IP) chemotherapy (TSIC) initiation with survival of patients with stage III epithelial ovarian cancer (EOC) patients using ancillary data from cooperative group clinical trials. Methods Data from 420 patients with stage III EOC treated with IP chemotherapy under GOG-0114 and 172 were reviewed. The Cox proportional hazards model was used to evaluate independent prognostic factors and estimate their covariate-adjusted effects on PFS and OS. Results The median TSIC was 62.5 days (interquartile range 28–83). The median TSIC was longer for patients in GOG-0114 vs those in GOG-172 (83 vs 26 days, p < 0.001). TSIC was significantly associated (p = 0.049) with PFS: each 10% increase in TSIC (days) decreases the risk of progression by 3%. TSIC was not significantly associated with OS in this model. In a linear regression model, gross residual disease was significantly associated with shorter TSIC (R2 − 0.141, 95%CI − 0.217, − 0.064, p < 0.001). When only data from GOG-172 were considered, no statistical significant association was found between TSIC and PFS or OS. Conclusions In this ancillary data study, TSIC was not associated with improved OS in patients with stage III epithelial ovarian cancer. TSIC was significantly associated with PFS for the entire cohort, suggesting increase in PFS with longer TSIC. However, this was not found when only data from GOG 172 or GOG 114 were analyzed separately. Hence, the relationship between IP chemotherapy initiation and time from surgery needs to be studied further.
KW - NRG Oncology
KW - Ovarian cancer
KW - Time interval between surgery and IP chemo
UR - http://www.scopus.com/inward/record.url?scp=84992359710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992359710&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2016.10.003
DO - 10.1016/j.ygyno.2016.10.003
M3 - Article
C2 - 27726923
AN - SCOPUS:84992359710
SN - 0090-8258
VL - 143
SP - 484
EP - 489
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 3
ER -